In patients with a coronary artery bypass graft (CABG) procedure prior to an acute coronary syndrome, alirocumab added to a statin was associated with significantly reduced events and mortality, according to a new analysis.
The primary ODYSSEY OUTCOMES results were presented last year, with the present analysis published in the Journal of the American College of Cardiology. The study included 18,924 patients who were between one month and one year post-acute coronary syndrome. Patients had an elevated atherogenic lipoprotein level despite high-intensity background statin therapy. They were randomized to either alirocumab or to placebo subcutaneously every two weeks. The primary composite study endpoint was major adverse cardiovascular events (MACE), comprised of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization. The authors also categorized the patients by CABG status (no CABG, n=16,896; index CABG after qualifying acute coronary syndrome prior to randomization, n=1,025; or CABG before qulifying acute coronary syndrome, n=1,003). Media follow-up was 2.8 years.
According to the results, hazard ratios (all 95% confidence intervals) for MACE (no CABG=0.86 [0.78 to 0.95]; index CABG=0.85 [0.54 to 1.35]; prior CABG=0.77 [0.61 to 0.98]) and death (0.88 [0.75 to 1.03]; 0.85 [0.46 to 1.59]; 0.67 [0.44 to 1.01], respectively) were “consistent with the overall trial results,” according to the researchers. Absolute risk differed across CABG categories.
“Among patients with recent ACS and elevated atherogenic lipoproteins despite intensive statin therapy, alirocumab was associated with large absolute reductions in MACE and death in those with CABG preceding the acute coronary syndrome event,” the authors concluded.
Effects of Alirocumab on CVE After CABG| JACC. These multivessel disease pts benefits from intensive decrease of LDL-c #lipids #PCSK9i https://t.co/rDZhyU38yp
— SABOURETCardiologist (@SABOURETCardio) September 11, 2019
#JACC Editors’ Insights: Does prior CABG status impact the benefits of adding of PCSK9i alirocumab to max intensity status? It may change your practice. What do you think? https://t.co/yqJsZ3xkbb @gabrielsteg pic.twitter.com/BRoxvJNNIl
— JACC Journals (@JACCJournals) September 11, 2019
📌Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. #Alirocumab was associated with large absolute reductions in MACE and death in those with #CABG preceding the ACS event. https://t.co/lwedND484f pic.twitter.com/X5dNfunsNa
— Rosa Fernandez (@MAROSFO) August 29, 2019
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.